Peak-dose Dyskinesia
Peak-dose Dyskinesia - Related Videos
03:43
Induction of Levodopa-Induced Dyskinesias in a Rat Model of Parkinson's Disease
0 Views •
2025
This video demonstrates the process of inducing levodopa-induced dyskinesias in a Parkinson's rat model by administering levodopa alongside a dopamine conversion inhibitor. Repeated injections overstimulate the brain neurons, resulting in motor dysfunction.
05:52
Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
0 Views •
Cited by 34 •
2013
Handwriting analysis software significantly improves upon existing instruments measuring movement disorders. Individuals at risk for psychosis and healthy controls completed handwriting tasks to test for dyskinesia. Results suggest that youth at risk for psychosis exhibit dyskinesia and that handwriting analysis could significantly contribute to wider dissemination of early identification...
01:08
IR Spectrum Peak Splitting: Symmetric vs Asymmetric Vibrations
0 Views •
2024
Identical bonds within a polyatomic group can stretch symmetrically (in-phase) or asymmetrically (out-of-phase). Similar to hydrogen bonding, these vibrations also influence the shape of the IR peak. Generally, asymmetric stretching frequencies are higher than symmetric stretching frequencies. For example, primary amines exhibit two distinct IR peaks between 3300–3500 cm−1 corresponding to the symmetric and asymmetric N-H stretching, while secondary amines exhibit a single stretching vibration...
01:20
IR Spectrum Peak Intensity: Dipole Moment
0 Views •
2024
The dipole moment of a bond is the product of the partial charge on either atom and the distance between them. Dipole moments influence the efficiency of IR absorption and the peak intensity. When a bond with a dipole moment is placed in an electric field, the direction of the field determines if the bond is compressed or stretched. Electromagnetic radiation consists of an electric field component that rapidly reverses direction. It follows that polar bonds are alternately stretched and...
00:55
IR Spectrum Peak Intensity: Amount of IR-Active Bonds
0 Views •
2024
When infrared radiation is passed through a molecule, absorption occurs if the molecule's vibration leads to a substantial change in its bond dipole moment. Transitions between vibrational energy levels, typically corresponding to infrared frequencies (4000–400 cm−1), allow absorption if the vibration significantly alters the dipole moment, making the molecule infrared active. The molecular bonds have different stretching and bending vibrations, resulting in various peaks with varying...
FAQs
The therapeutic threshold marks the dopamine replacement level at which motor benefit can shift toward involuntary movement. Because this threshold differs among people with Parkinson’s disease, the same levodopa exposure may remain useful for one person but exceed the tolerable range for another. This relationship helps explain why treatment decisions must be individualized rather than based only on a standard dose.
Repeated dopaminergic stimulation alters signaling within basal ganglia circuits, which are central to motor control. Over time, these changes can make movement output more vulnerable when levodopa levels become high. The resulting dyskinesia therefore reflects both the immediate medication level and longer-term adaptations in neural signaling, making the condition relevant to studies of motor circuit biology.
The movements may involve the limbs, trunk, face, or neck, and their twisting or dance-like quality can vary across these regions. Documenting where the movements appear adds useful information beyond simply noting that they occur. Regional patterns can help describe the motor phenotype and clarify how the altered basal ganglia signaling is expressed through different parts of the body.
Clinicians examine whether involuntary movements arise during the medication’s on period and whether they coincide with the highest levodopa levels. This timing relationship distinguishes a peak-related response from symptoms occurring at other points in the dosing cycle. Careful observation of dose timing and movement onset provides a practical basis for interpreting the patient’s response to therapy.
When movements appear at levodopa’s highest effect, clinicians may reconsider the size of individual doses or the dosing schedule. These changes aim to address exposure that exceeds the person’s therapeutic threshold while preserving useful motor benefit. If dose or schedule changes do not resolve the problem, clinicians can evaluate alternative treatment approaches as part of individualized decision-making.
The condition provides a model for examining how dopamine signaling, basal ganglia circuits, and motor control interact during long-term Parkinson’s therapy. Researchers can relate the timing of involuntary movements to levodopa exposure and altered circuit responses. This makes peak-dose dyskinesia useful for studying both the biology of movement and the longer-term effects of dopaminergic treatment.